On May 12, 2025, Maxim Group, a leading financial services firm, has initiated coverage on ProMIS Neurosciences (PMN, Financial). The firm has announced a "Buy" rating for the stock, signaling a positive outlook for the company's future growth prospects.
Analyst Jason McCarthy, representing Maxim Group, has set a price target of USD 3.00 for ProMIS Neurosciences (PMN, Financial). This price target reflects the analyst's expectations for the company's stock performance in the coming period.
ProMIS Neurosciences (PMN, Financial) does not have a previous rating or price target from Maxim Group, indicating this is the initial coverage by the analyst. The coverage initiation and the "Buy" rating could potentially influence investor sentiment and trading activity for PMN shares on the market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for ProMIS Neurosciences Inc (PMN, Financial) is $7.00 with a high estimate of $8.00 and a low estimate of $6.00. The average target implies an upside of 1,294.42% from the current price of $0.50. More detailed estimate data can be found on the ProMIS Neurosciences Inc (PMN) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, ProMIS Neurosciences Inc's (PMN, Financial) average brokerage recommendation is currently 1.3, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
